Article
Clinical Neurology
Rita Perelroizen, Bar Philosof, Noga Budick-Harmelin, Tom Chernobylsky, Ariel Ron, Rotem Katzir, Dor Shimon, Adi Tessler, Orit Adir, Anat Gaoni-Yogev, Tom Meyer, Avivit Krivitsky, Nuphar Shidlovsky, Asaf Madi, Eytan Ruppin, Lior Mayo
Summary: This study reveals that depletion of reactive astrocytes can lead to regression of glioblastoma and prolonged survival. It also demonstrates that glioma cells depend on astrocyte-derived cholesterol for survival. The findings highlight the important role of astrocytes in controlling the pathogenicity of glioblastoma.
Article
Cell Biology
Xiang-Yu Gao, Jian Zang, Min-Hua Zheng, Yu-Fei Zhang, Kang-Yi Yue, Xiu-Li Cao, Yuan Cao, Xin-Xin Li, Hua Han, Xiao-Fan Jiang, Liang Liang
Summary: Glioma stem cells formation is promoted by TMZ treatment through upregulation of HMGB1, which activates the TLR2/NEAT1/Wnt pathway, providing a potential therapeutic target for preventing TMZ resistance in GBM patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Cell & Tissue Engineering
Sijia Li, Lihua Dong, Zhenyu Pan, Guozi Yang
Summary: Background: Glioblastoma, a common and aggressive adult brain tumor, has a high recurrence rate and low survival rate despite conventional treatment. Accumulating evidence suggests that the subventricular zone, which contains neural stem cells and glioma stem cells, plays a crucial role in recurrence and treatment resistance.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Qiong Wu, Anders E. Berglund, Robert J. Macaulay, Arnold B. Etame
Summary: This study provides evidence that the epigenetic reactivation of Tumor Suppressor Candidate 3 (TUSC3) can reprogram the sensitivity of glioblastoma stem cells (GSCs) to Temozolomide (TMZ), regardless of the promoter methylation status of the DNA repair gene O6-methylguanine DNA methyltransferase (MGMT). These findings offer a framework for further exploring TUSC3-mediated epigenetic reprogramming strategies to enhance TMZ sensitivity and outcomes in glioblastoma multiforme (GBM).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Hyunkoo Kang, Haksoo Lee, Dahye Kim, Byeongsoo Kim, JiHoon Kang, Hae Yu Kim, HyeSook Youn, BuHyun Youn
Summary: Glioblastoma (GBM) is a highly malignant brain tumor that is resistant to current therapies. This review focuses on the resistance mechanisms of GBM, particularly towards temozolomide (TMZ), and summarizes the recent findings on the intrinsic and extrinsic mechanisms of chemoresistance in GBM stem cells (GSCs). It also discusses novel therapeutic strategies, such as molecular targeting, autophagy inhibition, oncolytic viral therapy, drug repositioning, and targeting of GSC niches, to eliminate GSCs and improve GBM therapy.
Review
Biochemistry & Molecular Biology
Zeyu Wang, Hao Zhang, Shengchao Xu, Zhixiong Liu, Quan Cheng
Summary: Glioblastoma stem cells pose a challenge in therapy resistance, with different subtypes or metabolic patterns potentially leading to varying sensitivity. Involvement of neural stem cells in tumor resistance to treatments is also a possibility.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Review
Oncology
Olga Renner, Markus Burkard, Holger Michels, Claudia Vollbracht, Tobias Sinnberg, Sascha Venturelli
Summary: Standard therapy for glioblastoma typically results in limited survival and quality of life improvements, but pharmacological ascorbate shows potential efficacy. The biological complexity and resistance of glioblastoma calls for further research to confirm ascorbate's potential as a therapeutic agent.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Haohao Huang, Songyang Zhang, Yuanyuan Li, Zhaodan Liu, Lanjuan Mi, Yan Cai, Xinzheng Wang, Lishu Chen, Haowen Ran, Dake Xiao, Fangye Li, Jiaqi Wu, Tingting Li, Qiuying Han, Liang Chen, Xin Pan, Huiyan Li, Tao Li, Kun He, Ailing Li, Xuemin Zhang, Tao Zhou, Qing Xia, Jianghong Man
Summary: Prohibitin regulates mitochondrial ROS production by stabilizing the peroxidase PRDX3, contributing to radiotherapy resistance in glioma stem-like cells.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Jonathan P. S. Knisely, Howard A. Fine
Summary: The Oncology Grand Rounds series aims to provide clinical context to original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, literature reviews, and suggested management approaches by the authors. The goal is to help readers apply key study findings, including those from the Journal of Clinical Oncology, to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Cell Biology
Karina Biserova, Arvids Jakovlevs, Romans Uljanovs, Ilze Strumfa
Summary: Cancer stem cells, particularly in glioblastoma, play a crucial role in tumor resistance to treatment and recurrence. The regulatory mechanisms of glioma stem cells include tumor microenvironment, niche concept, metabolism, immunity, genetics, and epigenetics, which serve as potential targets for future treatments.Understanding the molecular markers and treatment resistance of GSCs in glioblastoma may lead to more effective therapeutic strategies in the future.
Article
Biochemistry & Molecular Biology
Parveen Kumar, Vivek Verma, Dheeraj Mohania, Surbhi Gupta, Avneet K. Babbar, Bhawna Rathi, Rakesh S. Dhanda, Manisha Yadav
Summary: The study revealed that RUNX1T1 is mutated in different cancers and associated with poor overall survival in glioma patients, possibly affecting glioma growth and development through HIF1α regulation. Experimental results showed that downregulation of RUNX1T1 may lead to degradation of HIF1α, reducing proliferation and invasiveness of glioblastoma cells.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2021)
Article
Cell Biology
I de Souza, L. K. S. Monteiro, C. B. Guedes, M. M. Silva, M. Andrade-Tomaz, B. Contieri, M. T. Latancia, D. Mendes, B. F. M. M. Porchia, M. Lazarini, L. R. Gomes, C. R. R. Rocha
Summary: The study reveals the role of NRF2 in modulating ferroptosis in glioblastoma cells, as well as its correlation with ABCC1 expression. Moreover, high levels of NRF2 result in collateral sensitivity and contribute to GSH depletion when the system xc(-) is blocked. These findings suggest that ferroptosis induction could be a potential therapeutic strategy to reverse drug resistance in gliomas.
CELL DEATH & DISEASE
(2022)
Review
Biochemistry & Molecular Biology
Noelia Geribaldi-Doldan, Irati Hervas-Corpion, Ricardo Gomez-Oliva, Samuel Dominguez-Garcia, Felix A. Ruiz, Irene Iglesias-Lozano, Livia Carrascal, Ricardo Pardillo-Diaz, Jose L. Gil-Salu, Pedro Nunez-Abades, Luis M. Valor, Carmen Castro
Summary: GBM is a common and aggressive primary brain tumor with poor prognosis. GSCs, which are resistant to current treatments, have been identified as the origin of GBM. Targeting PKC may be an effective approach to treat recurrent GBM.
Article
Multidisciplinary Sciences
Mohammad Hazaymeh, Ronja Loeber-Handwerker, Katja Doering, Tammam Abboud, Dorothee Mielke, Veit Rohde, Vesna Malinova
Summary: Approximately 25% of glioblastomas show corpus callosum infiltration at diagnosis, which is associated with poor prognosis. The extent of corpus callosum involvement ranges from partial unilateral to complete bilateral infiltration. The role of surgery in glioblastoma with corpus callosum involvement is controversial.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, Research & Experimental
Fangting You, Cheng Li, Shicheng Zhang, Qiaoshan Zhang, Zhiyuan Hu, Yuhui Wang, Tong Zhang, Qingming Meng, Rutong Yu, Shangfeng Gao
Summary: In this study, we investigated the efficacy of an antidiabetic drug Sitagliptin in inhibiting the survival, stemness, and autophagy of GBM cells and enhancing the cytotoxicity of TMZ. The results showed that Sitagliptin can effectively inhibit cell proliferation, induce apoptosis, suppress self-renewal and stemness of GSCs. Furthermore, Sitagliptin could inhibit TMZ-induced protective autophagy and enhance the cytotoxicity of TMZ in glioma cells.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Nanoscience & Nanotechnology
Youngee Seo, Lida Ghazanfari, Alyssa Master, Hemant M. Vishwasrao, Xiaomeng Wan, Marina Sokolsky-Papkov, Alexander Kabanov
Summary: This study reports the development of a novel theranostic system called NanoFerrogels, which combines magnetic nanoparticles and polymeric micelles for cancer diagnosis and treatment. NanoFerrogels function as imaging agents for magnetic resonance imaging and as drug loading compartments. The experiments demonstrate the potential of NanoFerrogels as a remotely actuated theranostic platform for cancer therapy.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2022)
Article
Chemistry, Multidisciplinary
Kin Man Au, Roland Tisch, Andrew Z. Wang
Summary: Failure to establish immune tolerance can lead to autoimmune diseases. This study demonstrates a potential new strategy for treating autoimmune diseases by bioengineering programmed death-ligand 1 (PD-L1)- and cluster of differentiation 86 (CD86)-functionalized mouse Schwann cells (SCs) to modify disease progression and ameliorate symptoms without inducing systemic immunosuppression.
ADVANCED MATERIALS
(2022)
Article
Medicine, Research & Experimental
Liu Zhou, Ruiling Long, Mei Hu, Nan Liu, Yue Feng, Lin Qiu, Zibo Li, Yue Chen, Li Wang
Summary: Boron neutron capture therapy (BNCT) is a promising cancer treatment strategy that utilizes boron-containing ligands. In this study, a series of substituted boramino acids were synthesized and evaluated for their potential use in BNCT with integrated positron emission tomography (PET). The compound R-[F-18]-5a demonstrated the best tumor uptake and stability among tested agents, making it a promising candidate for future evaluation in PET and BNCT combination therapy.
MOLECULAR PHARMACEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Li Wang, Yubai Zhou, Xuedan Wu, Xinrui Ma, Bing Li, Ransheng Ding, Michael A. Stashko, Zhanhong Wu, Xiaodong Wang, Zibo Li
Summary: MerTK is abnormally expressed in various cancers, but the sensitivity of tumors to MerTK suppression may vary. In this study, a radiolabeled agent [F-18]-MerTK-6 was developed and showed prominent uptake in tumors in initial evaluation, suggesting it as a promising PET agent for MerTK imaging.
Article
Biotechnology & Applied Microbiology
Pritha Agarwalla, Edikan A. Ogunnaike, Sarah Ahn, Kristen A. Froehlich, Anton Jansson, Frances S. Ligler, Gianpietro Dotti, Yevgeny Brudno
Summary: This study introduces a novel implantable multifunctional scaffold (MASTER) that streamlines in vivo CAR-T cell manufacturing, resulting in the rapid generation and release of functional CAR-T cells in mice. MASTER shows improved therapeutic efficacy and persistence compared to conventional CAR-T cells, promising to transform CAR-T cell therapy.
NATURE BIOTECHNOLOGY
(2022)
Article
Multidisciplinary Sciences
Hongxia Li, Emily B. Harrison, Huizhong Li, Koichi Hirabayashi, Jing Chen, Qi-Xiang Li, Jared Gunn, Jared Weiss, Barbara Savoldo, Joel S. Parker, Chad Pecot, Gianpietro Dotti, Hongwei Du
Summary: Therapeutic options for non-small cell lung cancer patients with brain metastases are limited. CAR-T cells targeting B7-H3 and expressing the chemokine receptor CCR2b show improved accumulation in the brain and enhanced anti-tumor activity. This strategy could improve the efficacy of adoptive T-cell therapies in patients with solid tumors presenting with brain metastases.
NATURE COMMUNICATIONS
(2022)
Article
Materials Science, Biomaterials
Devika M. Varma, Cole J. Batty, Rebeca T. Stiepel, Elizabeth G. Graham-Gurysh, John A. Roque, Erik S. Pena, M. Shamim Hasan Zahid, Kunyu Qiu, Aaron Anselmo, David B. Hill, Ted M. Ross, Eric M. Bachelder, Kristy M. Ainslie
Summary: This study investigates the use of nasal gel formulation for influenza vaccination and demonstrates that nasal gel can generate rapid serum and mucosal humoral immune responses.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2022)
Article
Veterinary Sciences
Gregory A. Krane, Keith R. Shockley, David E. Malarkey, Andrew D. Miller, C. Ryan Miller, Debra A. Tokarz, Heather L. Jensen, Kyathanahalli S. Janardhan, Matthew Breen, Christopher L. Mariani
Summary: The study aimed to assess the agreement among pathologists in diagnosing canine gliomas. The results showed that there was a moderate overall agreement among pathologists when using CBTC guidelines for diagnosing canine gliomas, with higher agreement for oligodendrogliomas and astrocytomas compared to undefined gliomas.
VETERINARY AND COMPARATIVE ONCOLOGY
(2022)
Correction
Oncology
Benjamin Lin, Julia Ziebro, Erin Smithberger, Kasey R. Skinner, Eva Zhao, Timothy F. Cloughesy, Zev A. Binder, Donald M. O'Rourke, David A. Nathanson, Frank B. Furnari, C. Ryan Miller
Article
Multidisciplinary Sciences
Pravin Kesarwani, Shiva Kant, Yi Zhao, Antony Prabhu, Katie L. Buelow, C. Ryan Miller, Prakash Chinnaiyan
Summary: Considerable scientific effort has been devoted to understanding the biological consequences and therapeutic implications of abnormal tryptophan metabolism in brain tumors and neurodegenerative diseases. This study focuses on the downstream metabolism of tryptophan and the accumulation of quinolinate (QA) in glioblastoma, which was found to play a critical role in promoting immune tolerance and supporting tumor growth. Inhibition of QA production through targeting kynureninase may offer a promising therapeutic strategy to reverse the immune suppressive microenvironment in glioblastoma.
NATURE COMMUNICATIONS
(2023)
Article
Cell Biology
Nazira El-Hage, Matthew J. Haney, Yuling Zhao, Myosotys Rodriguez, Zhanhong Wu, Mori Liu, Carson J. Swain, Hong Yuan, Elena V. Batrakova
Summary: We have developed a novel EV-based drug delivery system for the treatment of Batten disease (BD) by transporting the lysosomal enzyme TPP1. The EVs were loaded with TPP1 through transfection of parent cells and showed successful delivery to the brain in a mouse model of BD. The TPP1-loaded EVs exhibited therapeutic effects by eliminating lipofuscin aggregates, reducing inflammation, and improving neuronal survival, possibly through activation of the autophagy pathway. Continued research into effective therapies for BD is crucial for improving patient outcomes.
Meeting Abstract
Oncology
Pravin Kesarwani, Shiva Kant, Antony Prabhu, Katie L. Buelow, C. Ryan Miller, Prakash Chinnaiyan
Meeting Abstract
Oncology
K. J. Lee, C. T. Stackhouse, J. C. Anderson, R. Bash, Z. Yue, T. Nguyen, N. J. Eustace, L. Ianov, C. P. Langford, J. Wang, C. Xing, E. S. Yang, A. B. Hjelmeland, C. R. Miller, J. Y. Chen, G. Y. Gillespie, C. Willey
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Meeting Abstract
Oncology
Pravin Kesarwani, Yi Zhao, Shiva Kant, C. Ryan Miller, Prakash Chinnaiyan
Meeting Abstract
Oncology
Pravin Kesarwani, Shiva Kant, Yi Zhao, Antony Prabhu, Katie Buelow, C. Ryan Miller, Prakash Chinnaiyan